AR005147A1 - Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso. - Google Patents

Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso.

Info

Publication number
AR005147A1
AR005147A1 ARP960105774A ARP960105774A AR005147A1 AR 005147 A1 AR005147 A1 AR 005147A1 AR P960105774 A ARP960105774 A AR P960105774A AR P960105774 A ARP960105774 A AR P960105774A AR 005147 A1 AR005147 A1 AR 005147A1
Authority
AR
Argentina
Prior art keywords
danofloxacin
pharmaceutically acceptable
acceptable salts
aqueous pharmaceutical
solution including
Prior art date
Application number
ARP960105774A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR005147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR005147A1 publication Critical patent/AR005147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Soluciones farmaceuticas acuosas adecuadas para inyeccion en un huesped, que tienen mejorada la tolerancia en el sitio de la inyeccion, comprendendanofloxacina o sus sales farmaceuticamente aceptables y un compuesto de magnesio o de cinc. E lcompuesto de cinc requiere ademas la presencia de undisolvente complementario.
ARP960105774A 1995-12-21 1996-12-19 Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso. AR005147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
AR005147A1 true AR005147A1 (es) 1999-04-14

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105774A AR005147A1 (es) 1995-12-21 1996-12-19 Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso.

Country Status (42)

Country Link
US (1) US5811130A (es)
EP (1) EP0868183B1 (es)
JP (1) JP3416145B2 (es)
KR (1) KR100402570B1 (es)
CN (1) CN1104899C (es)
AP (1) AP706A (es)
AR (1) AR005147A1 (es)
AT (1) ATE212551T1 (es)
AU (1) AU709474B2 (es)
BG (1) BG63933B1 (es)
BR (1) BR9612230A (es)
CA (1) CA2239352C (es)
CO (1) CO4480098A1 (es)
CZ (1) CZ293747B6 (es)
DE (1) DE69618987T2 (es)
DK (1) DK0868183T3 (es)
DZ (1) DZ2146A1 (es)
EG (1) EG24071A (es)
ES (1) ES2167609T3 (es)
GT (1) GT199600098A (es)
HR (1) HRP960607B1 (es)
HU (1) HU227918B1 (es)
IL (1) IL124454A (es)
IS (1) IS2010B (es)
MA (1) MA24035A1 (es)
MX (1) MX9805026A (es)
MY (1) MY117109A (es)
NO (1) NO315734B1 (es)
NZ (2) NZ501160A (es)
OA (1) OA10697A (es)
PE (1) PE25798A1 (es)
PL (1) PL186795B1 (es)
PT (1) PT868183E (es)
RS (1) RS49523B (es)
RU (1) RU2141827C1 (es)
SI (1) SI0868183T1 (es)
SK (1) SK284412B6 (es)
TN (1) TNSN96163A1 (es)
TW (1) TW449475B (es)
UA (1) UA56151C2 (es)
WO (1) WO1997023217A1 (es)
ZA (1) ZA9610780B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
EP1524997A1 (en) * 2002-06-26 2005-04-27 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
CA2572167A1 (en) * 2004-07-02 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Quinolone-containing medicinal composition
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
MX2008010222A (es) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195020A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
CA2988092A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
WO2018146194A1 (en) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
CA2072366C (en) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Carboxylic acid-metal ion-acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
DE69102900T3 (de) * 1990-02-14 1998-04-09 Takeda Chemical Industries Ltd Brausemischung, deren Herstellung sowie Verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HUP9903726A3 (en) 2001-01-29
KR19990076617A (ko) 1999-10-15
ES2167609T3 (es) 2002-05-16
TNSN96163A1 (fr) 2005-03-15
IS2010B (is) 2005-05-13
PE25798A1 (es) 1998-05-21
JP3416145B2 (ja) 2003-06-16
DZ2146A1 (fr) 2002-10-23
HU227918B1 (en) 2012-06-28
CO4480098A1 (es) 1997-07-09
DE69618987T2 (de) 2002-11-21
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
NO315734B1 (no) 2003-10-20
SK284412B6 (sk) 2005-03-04
NO982842L (no) 1998-06-19
MX9805026A (es) 1998-09-30
CZ193098A3 (cs) 1999-05-12
JPH11501331A (ja) 1999-02-02
BG102542A (en) 1999-06-30
NZ320545A (en) 2000-03-27
KR100402570B1 (ko) 2003-12-18
ATE212551T1 (de) 2002-02-15
PL328001A1 (en) 1999-01-04
TW449475B (en) 2001-08-11
CZ293747B6 (cs) 2004-07-14
BG63933B1 (bg) 2003-07-31
EG24071A (en) 2008-05-11
CA2239352A1 (en) 1997-07-03
IL124454A0 (en) 1998-12-06
CN1104899C (zh) 2003-04-09
HUP9903726A2 (hu) 2000-04-28
OA10697A (en) 2001-05-04
IL124454A (en) 2003-10-31
CA2239352C (en) 2002-06-04
HRP960607B1 (en) 2002-06-30
YU69096A (sh) 1999-06-15
DE69618987D1 (de) 2002-03-14
UA56151C2 (uk) 2003-05-15
SK80798A3 (en) 1999-09-10
BR9612230A (pt) 1999-07-13
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
US5811130A (en) 1998-09-22
HRP960607A2 (en) 1998-06-30
WO1997023217A1 (en) 1997-07-03
NZ501160A (en) 2001-10-26
SI0868183T1 (en) 2002-04-30
MY117109A (en) 2004-05-31
NO982842D0 (no) 1998-06-19
AU7328996A (en) 1997-07-17
GT199600098A (es) 1998-06-12
IS4755A (is) 1998-05-25
DK0868183T3 (da) 2002-03-25
ZA9610780B (en) 1998-06-22
PL186795B1 (pl) 2004-02-27
CN1205636A (zh) 1999-01-20
RU2141827C1 (ru) 1999-11-27
AP9600898A0 (en) 1997-01-31
PT868183E (pt) 2002-06-28
EP0868183B1 (en) 2002-01-30
MA24035A1 (fr) 1997-07-01

Similar Documents

Publication Publication Date Title
AR005147A1 (es) Una solución farmacéutica acuosa inyectable que comprende danofloxacina o una de sus sales farmacéuticamente aceptables y su uso.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ES2191682T3 (es) Nueva formulacion farmaceutica.
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
MX9207263A (es) Sistema para el suministro de una substancia activa para la liberacion sostenida.
AR046970A1 (es) Esteres de fosfato de florfenicol
ES2171590T3 (es) Composicion farmaceutica para el tratamiento de rinitis agudas, que contiene un simpatomimetico y pantotenol y/o acido pantotenico.
AR002982A1 (es) Benzonitrilos y benzofluoruros, un procedimiento para prepararlos, su empleo para preparar médicamentos, un médicamento hecho a base de estos compuestos, las preparaciónes farmacéuticas que los contienen y un procedimiento para obtener estas preparaciónes farmacéuticas.
IS2216B (is) Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
ES2131517T3 (es) Composicion farmaceutica de uso oftalmologico que comprende un agente antiinflamatorio no esteroide y un agente anticongestivo.
EA199900580A1 (ru) Фармацевтические производные аминофосфоновой кислоты
ES2148512T3 (es) Complejos de inclusion multicomponentes de alta solubilidad que constan de una sustancia farmaceutica acidica, una ciclodextrina y una base.
PA8451701A1 (es) Formulacion inyectable transparente de compuesto anestesico
ITBO950533A0 (it) Siringa per iniezioni ipodermiche.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
BR9910201A (pt) Sistema terapêutico transdérmico para emprego de candesartan
ES2523428T3 (es) Parche para administración transdérmica
ES2098115T3 (es) Esteres de acil l-carnitina y composiciones farmaceuticas que los contienen para tratamiento de shock endotoxico.
PT1014951E (pt) Composicao de revestimento farmaceutica e metodo para a sua utilizacao
MX9203735A (es) Una forma de dosis mejorada para suministrar una droga o un agente terapeutico a un ambiente de uso.
ES1024074Y (es) Nueva jeringuilla hipodermica de un solo uso.

Legal Events

Date Code Title Description
FG Grant, registration